Quantitative 2- and 3-dimensional analysis of pharmacokinetic model-derived variables for breast lesions in dynamic, contrast-enhanced MR mammography

European Journal of Radiology

Volumn 66, Issue 2, 2008, Pages 300-308

  Hauth, E A M ^a   Jaeger, H J ^b   Maderwald, S ^a   Muehler, A ^c   Kimmig, R ^a   Forsting, M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MARIEN HOSPITAL WESEL   (Germany)

^c ICAD INC   (United States)

Author keywords

Computer assisted; Diagnosis; Magnetic resonance imaging; Mammography

Indexed keywords

BIOMEDICAL ENGINEERING; DIAGNOSIS; MAGNETIC RESONANCE IMAGING; PHARMACOKINETICS; PIXELS;

BENIGN LESIONS; COLOR INTENSITY; PHARMACOKINETIC PARAMETERS; VASCULAR PERMEABILITY;

MAMMOGRAPHY;

ADULT; AGED; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST LESION; CONTROLLED STUDY; EXTRACELLULAR SPACE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

ADULT; AGED; BREAST DISEASES; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; REGRESSION ANALYSIS; ROC CURVE;

EID: 43049087420     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2007.05.026     Document Type: Article

References (33)

1. Orel S.G. Differentiating benign from malignant enhancing lesions identified at MR imaging of the breast: Are time-signal-intensity curves an accurate predictor?. Radiology 211 (1999) 5-7
2. Gilles R., Guinebretiere J.M., Lucidarme O., et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 191 3 (1994) 625-631
3. Boetes C., Barentsz J.O., Mus R.D., et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 193 3 (1994) 777-781
4. Orel S.G., Schnall M.D., LiVolsi V.A., et al. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 190 2 (1994) 485-493
5. Mussurakis S., Buckley D.L., and Horsman A. Dynamic MRI of invasive breast cancer: assessment of three region-of-interest analysis methods. J Comput Assist Tomogr 21 3 (1997) 431-438
6. Vomweg T.W., Teifke A., Schreiber W.G., et al. Combination of low and high resolution T1-weighted sequences for improved evaluation of morphologic criteria in dynamic contrast enhanced MRI of the breast. Rofo 174 11 (2002) 1445-1449
7. Degani H., Gusis V., Weinstein D., et al. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 3 7 (1997) 780-782
8. Furman-Haran E., Grobgeld D., Kelcz F., and Degani H. Critical role of spatial resolution in dynamic contrast-enhanced breast MRI. J Magn Reson Imaging 13 6 (2001) 862-867
9. Weinstein D., Strano S., Cohen P., et al. Breast fibroadenoma: mapping of pathophysiologic features with three-time-point, contrast-enhanced MR imaging-pilot study. Radiology 210 1 (1999) 233-240
10. Holland A.E., Hendrick R.E., Jin H., et al. Correlation of high-resolution breast MR imaging with histopathology; validation of a technique. J Magn Reson Imaging 11 6 (2000) 601-606
11. Kuhl C.K., Bieling H.B., Lutterbey G., et al. Standardization and acceleration of quantitative analysis of dynamic MR mammographies via parametric images and automatized ROI definition. Rofo 164 6 (1996) 475-482
12. Furman-Haran E., Grobgeld D., and Degani H. Dynamic contrast-enhanced imaging and analysis at high spatial resolution of MCF7 human breast tumors. J Magn Reson 128 2 (1997) 161-171
13. Hauth E.A., Stockamp C., Maderwald S., et al. Evaluation of the three-time-point method for diagnosis of breast lesions in contrast-enhanced MR mammography. Clin Imaging 30 3 (2006) 160-165
14. Furman-Haran E., Grobgeld D., Margalit R., et al. Response of MCF7 human breast cancer to tamoxifen: evaluation by the three-time-point, contrast-enhanced magnetic resonance imaging method. Clin Cancer Res 4 (1994) 2299-2304
15. Tofts P.S., and Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17 2 (1991) 357-367
16. Tofts P.S., Berkowitz B., and Schnall M.D. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33 4 (1995) 564-568
17. Padhani A.R., Gapinski C.J., Macvicar D.A., et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55 2 (2000) 99-109
18. Kelcz F., Furman-Haran E., Grobgeld D., and Degani H. Clinical testing of high-spatial-resolution parametric contrast-enhanced MR imaging of the breast. AJR Am J Roentgenol 179 6 (2002) 1485-1492
19. Furman-Haran E., and Degani H. Parametric analysis of breast MRI. J Comput Assist Tumogr 26 (2002) 376-386
20. Tofts P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7 1 (1997) 91-101
21. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 3 (1999) 223-232
22. Stevenson J.P., Rosen M., Sun W., et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21 (2003) 4428-4438
23. Liu G., Rugo H.S., Wilding G., et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23 (2005) 5464-5473
24. Weinmann H.J., Laniado M., and Mutzel W. Pharmacokinetics of GdDTPA/Dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16 (1984) 167-172
25. Tofts P.S., Shuter B., and Pope J.M. Ni-DTPA doped agarose gel-a phantom material for Gd-DTPA enhancement measurements. Magn Reson Imaging 11 (1993) 125-133
26. Teifke A., Behr O., Schmidt M., et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 239 2 (2006) 351-360
27. Furman-Haran E., Schechtman E., Kelcz F., et al. Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer 104 4 (2005) 708-718
28. Liberman L., Mason G., Morris E.A., et al. Does size matter? Positive predictive value of MRI-detected breast lesions as a function of lesion size. AJR Am J Roentgenol 186 2 (2006) 426-430
29. Rosset A., Spadola L., Pysher L., and Ratib O. Informatics in radiology (infoRAD): navigating the fifth dimension: innovative interface for multidimensional multimodality image navigation. Radiographics 26 1 (2006) 299-308
30. Birdwell R.L., Ikeda D.M., O'Shaughnessy K.F., et al. Mammographic characteristics of 115 missed cancers later detected with screening mammography and the potential utility of computer-aided detection. Radiology 219 1 (2001) 192-202
31. Obenauer S., Sohns C., Werner C., et al. Retrospective analysis of a computer-aided detection (CAD) system in full-field digital mammography in correlation to tumor histology. Rofo 177 8 (2005) 1103-1109
32. Szabo B.K., Wiberg M.K., Bone B., et al. Application of artificial neural networks to the analysis of dynamic MR imaging features of the breast. Eur Radiol 14 7 (2004) 1217-1225
33. Vomweg T.W., Teifke A., Kauczor H.U., et al. Self-organizing neural networks for automatic detection and classification of contrast (media) enhancement of lesions in dynamic MR-mammography. Rofo 177 5 (2005) 703-713